drugset / Trial / NCT02080455
Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.
RandomizedParallel-groupOpen-labelOther
Summary
The primary objective of this study is to assess the effect of atorvastatin, a weak cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK) of lomitapide and its 2 primary metabolites, M1 and M3.
Timeline
- Start
- 2014-01-27
- Primary completion
- 2014-03-07
- Completion
- 2014-03-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | 80 mg | Oral |
| Subject | lomitapide | Small molecule | 20 mg | Oral |
Indications
No indication recorded.